Compared to the non-ABx group, the ABx group had more patients with squamous cell carcinoma ([ABx group vs. Non-ABx group] 42.4% vs. 13.7%), tumor size of 40 mm or larger (72.7% vs. 38.1%), and elevated CRP (≥ 1.04 mg/dl) (75.8% vs. 45.2%). This evidence concerns the gene CRP and squamous cell carcinoma.